Lantern Pharma (NASDAQ: LTRN), a clinical-stage, AI-driven precision oncology company, has secured regulatory and Institutional Review Board approvals in Taiwan to initiate Part 2 of its Phase 2 HARMONIC trial of LP-300. The lead Taiwan site is now open to accrual and actively screening patients, with the company anticipating IRB approval at two additional sites during the fourth quarter. This development represents a significant step forward in Lantern's efforts to address the unmet needs of patients with the EGFR exon 21 L858R mutation, a subset of non-small cell lung cancer that often develops resistance to tyrosine kinase inhibitor therapy.
In the United States, a central IRB has approved the amended protocol, and clinical sites have begun identifying patients with the L858R mutation. Part 2 of the trial will enroll patients who have progressed after TKI treatment and will allow LP-300 to be administered for up to eight cycles in combination with carboplatin and pemetrexed, up from six cycles previously. This extension is based on preliminary data showing a median progression-free survival of 8.9 months among nine L858R patients who completed six cycles, compared with 8.3 months among all 16 L858R patients evaluated. While the company cautions that these findings are preliminary, exploratory, and based on small patient numbers, the results suggest a potential survival benefit that warrants further investigation.
The approvals in Taiwan and the amended protocol in the U.S. are important because they accelerate the clinical development of LP-300, a therapy that could fill a critical gap for patients with the L858R mutation, who currently have limited effective options after TKI failure. By leveraging its proprietary RADR artificial intelligence and machine-learning platform, Lantern aims to transform the cost, pace, and precision of oncology drug development. The RADR platform integrates large-scale genomic and biological data to identify patients most likely to benefit from Lantern's therapies, guiding biomarker-driven clinical development.
Lantern's pipeline includes LP-184 (zirdafulven), LP-300, and LP-284, along with its central-nervous-system-focused subsidiary, Starlight Therapeutics, and its AI subsidiary, Open-Medicine AI. The company's progress with LP-300 highlights the potential of AI-driven approaches to streamline drug development and deliver targeted therapies to patients who need them most.
For more details on Lantern Pharma and its initiatives, visit Lantern Pharma (NASDAQ: LTRN). The latest news and updates relating to LTRN are available in the company's newsroom at https://ibn.fm/LTRN. To view the full press release, visit https://ibn.fm/CqeDR.
As a specialized communications platform, BioMedWire focuses on the latest developments in biotechnology, biomedical sciences, and life sciences. It is part of the Dynamic Brand Portfolio at IBN, which provides access to wire solutions via InvestorWire, article and editorial syndication to 5,000+ outlets, enhanced press release enhancement, social media distribution, and tailored corporate communications solutions. For full terms of use and disclaimers, visit https://www.BioMedWire.com/Disclaimer.
